HM Payson & Co. Sells 15,789 Shares of Abbott Laboratories $ABT

HM Payson & Co. trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 354,529 shares of the healthcare product maker’s stock after selling 15,789 shares during the quarter. HM Payson & Co.’s holdings in Abbott Laboratories were worth $32,170,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Archford Capital Strategies LLC lifted its holdings in Abbott Laboratories by 17.2% during the 2nd quarter. Archford Capital Strategies LLC now owns 2,715 shares of the healthcare product maker’s stock worth $246,000 after purchasing an additional 398 shares during the last quarter. Asio Capital LLC bought a new position in shares of Abbott Laboratories in the second quarter worth $3,420,000. Radnor Capital Management LLC raised its position in shares of Abbott Laboratories by 4.3% in the 2nd quarter. Radnor Capital Management LLC now owns 19,792 shares of the healthcare product maker’s stock valued at $1,796,000 after buying an additional 807 shares in the last quarter. Activest Wealth Management lifted its stake in Abbott Laboratories by 91.9% during the second quarter. Activest Wealth Management now owns 856 shares of the healthcare product maker’s stock worth $78,000 after purchasing an additional 410 shares during the last quarter. Finally, Brown Miller Wealth Management LLC raised its holdings in shares of Abbott Laboratories by 0.9% during the 2nd quarter. Brown Miller Wealth Management LLC now owns 41,809 shares of the healthcare product maker’s stock worth $3,794,000 after buying an additional 370 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

Wall Street Analyst Weigh In

ABT has been the topic of several research analyst reports. TD Cowen reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Bank of America dropped their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Finally, Argus decreased their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $118.67.

Abbott Laboratories Trading Up 0.0%

Shares of NYSE ABT opened at $111.27 on Monday. The firm has a 50 day moving average price of $97.67 and a two-hundred day moving average price of $99.77. The stock has a market cap of $192.53 billion, a P/E ratio of 36.01, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.